Skip to main content
. 2014 Dec;20(12):2006–2014. doi: 10.3201/eid2012.140548

Table 3. Control studies of VPSPr inoculations to Tg(HuPrP)*.

Inoculum Tg(HuPrP) No. with clinical signs/total Histology, immunohistochemistry
PrPSc Western blot
No. positive/total Dpi 
positive/total† No. positive/total Dpi 
positive/total
Negative controls
None (129V)×8‡
0/15 0/9 0/721 ± 43 0/4 0/704 ± 43
Noninfectious
0/17
0/8
0/744 ± 15

0/5
0/749 ± 112
Positive controls
sCJDVV2§ (129V)×8 6/6 3/3 223 ± 13/223 ± 13 6/6 223 ± 11/223 ± 11
sCJDVV1 7/7 7/7 353 ± 12/353 ± 12 7/7 353 ± 12/353 ± 12
sCJDMM1 (129M)×2 3/3 3/3 183 ± 22/183 ± 22 3/3 183 ± 22/183 ± 22
sCJDMM2 3/3 3/3 609 ± 139/609 ± 139 3/3 609 ± 139/609 ± 139
sCJDMV2 (129V)×3 6/6 6/6 312 ± 4/312 ± 4 NA NA

Dpi, days postinoculation; M, methionine; V, valine; NA, not available; VPSPr, variably protease-sensitive prionopathy; sCJD sporadic Creutzfeldt-Jakob disease.
†Dpi of positive mice compared with dpi of all mice (including positive mice). Each value represents the mean ± SD.
‡Refers to the presence of V or M at PrP residue 129 and expression level indicated as × normal.
§Identifies the sCJD case-patients providing the inoculum.